Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis
Transplantation proceedings.
2001 May ;
33 (3) :
2179-81.
Language English Country United States Media print
Document type Clinical Trial, Journal Article
Persistent link
https://www.medvik.cz/link/pmid11377494
PubMed
11377494
DOI
10.1016/s0041-1345(01)01933-9
PII: S0041134501019339
Knihovny.cz E-resources
- MeSH
- Cyclophosphamide therapeutic use MeSH
- Cytarabine therapeutic use MeSH
- Adult MeSH
- Etoposide therapeutic use MeSH
- Granulocyte Colony-Stimulating Factor therapeutic use MeSH
- Adrenal Cortex Hormones therapeutic use MeSH
- Immunosuppressive Agents adverse effects therapeutic use MeSH
- Carmustine therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphocyte Depletion MeSH
- Magnetic Resonance Imaging MeSH
- Melphalan therapeutic use MeSH
- Hematopoietic Stem Cell Mobilization MeSH
- Multiple Sclerosis drug therapy therapy MeSH
- T-Lymphocytes immunology MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Patient Selection MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Names of Substances
- Cyclophosphamide MeSH
- Cytarabine MeSH
- Etoposide MeSH
- Granulocyte Colony-Stimulating Factor MeSH
- Adrenal Cortex Hormones MeSH
- Immunosuppressive Agents MeSH
- Carmustine MeSH
- Melphalan MeSH
References provided by Crossref.org
Journal of neurology.
2022 Jul ;
269 (7) :
3937-3958.
[epub] 20220411
